TABLE 2.

Summary of post-vaccine sera evaluated for neutralization potency by using pseudotyped VSV-Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Spike variants of concern (VOC).

Vaccine	Company	Spike construct	Number of samples	Time of sample collection	B.1.1.7a (Alpha)	P.1a (Gamma)	B.1.351a (Beta)	B.1.429a (Epsilon)	References
BNT162b2 BNT162b2	Pfizer/BioNTech Pfizer/BioNTech	2P 2P	37 21	3 weeks after 1st boost 3 weeks after 2nd boost	3.2-fold decrease 1.9-fold decrease	ND ND	ND ND	ND ND	Collier et al., 2021
mRNA-1273 NVX-CoV2373	Moderna Novavax	2P 3Q-2P	29 28	28 days after 2nd boost 2 weeks after 2nd boost	1-3-fold decrease 1-3 fold decrease	ND ND	ND ND	ND ND	Shen et al., 2021b
BBIBP-CorV CoronaVac	Sinopharm Sinovac	Native Native	25 25	2-3 weeks after 2nd boost 2-3 weeks after 2nd boost	Unchanged 0.7-fold change	ND ND	2.5-fold change 3.3-fold change	ND ND	Wang G.-L. et al., 2021
mRNA-1273 NVX-CoV2372	Moderna Novavax	2P 3Q-2P	26 23	28 days after 2nd boost 14 days after 2nd boost	ND ND	ND ND	9.7-fold decrease 14.5-fold decrease	2- fold decrease 2.5-fold decrease	Shen et al., 2021a
Sputnik V	Gamaleya	Native	12	1 month after 2nd boost	Unchanged	2.1-fold decrease	6.1-fold decrease	ND	Ikegame et al., 2021
mRNA-1273 BNT162b2	Moderna Pfizer/BioNTech	2P 2P	12 10	15 days after 2nd boost 7 days after 2nd boost	Unchanged Unchanged	ND ND	12.4-fold decrease 10.3-fold decrease	ND ND	Wang P. et al., 2021
BNT162b2 BNT162b2	Pfizer/BioNTech Pfizer/BioNTech	2P 2P	26 (23-55 year-old) 14 (57-73-year-old)	29 days after 2nd boost 43 days after 2nd boost	0.78-fold decrease 0.83-fold decrease	ND ND	ND ND	ND ND	Muik et al., 2021
mRNA-1273 BNT162b2	Moderna Pfizer/BioNTech	2P 2P	15 18	7-27 days after 2nd boost 7-27 days after 2nd boost	ND 1.3-fold reduction	ND 1.7-fold decrease	ND 3.2-fold decrease	2.2-fold decrease 2.9-fold decrease	McCallum et al., 2021

^aNeutralization assay (IC50 fold reduction compared to WT) in VOC, ND, not determined.